IDEAYA Biosciences, Inc. announced the appointment of Dr. Karlene Cimprich, Ph.D., and Dr. Kornelia Polyak, M.D., Ph.D., to its Scientific Advisory Board. Dr. Cimprich, Ph.D., is a Professor of Chemical and Systems Biology at Stanford University School of Medicine, and a member of Stanford'sCancer Institute. Her research focuses on understanding the mechanisms by which a cell maintains genome stability in the context of DNA replication, and how dysregulation of replication processes in cancer cells can inform therapeutic approaches.

Her work is relevant to IDEAYA's potential first-in-class pipeline programs in synthetic lethality DNA Damage Repair. Dr. Polyak, M.D, Ph.D., is a Professor of Medicine at Dana-Farber Cancer Institute, Harvard Medical School, a co-leader of the Cancer Cell Biology Program at the Dana-Farber Harvard Cancer Center, and a member of the National Academy of Sciences and the National Academy of Medicine. Her research is exploring breast cancer tumor biology, including tumor evolution and heterogeneity, and characterizing breast cancer risks to improve clinical management of breast cancer patients.

IDEAYA plans to clinically evaluate IDE161, its potential first-in-class inhibitor of poly (ADP-ribose) glycohydrolase (PARG), as monotherapy, including in BRCA1/2-mutant breast cancer patients. Other members of IDEAYA's Scientific Advisory Board, in addition to Drs. McCormick, Cimprich and Polyak, include Dr. William Sellers, M.D. (Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute, Harvard Medical School), Dr. Elizabeth Swisher, M.D. (University of Washington), and Dr. Trey Ideker, Ph.D. (University of California at San Diego).